IRIS
ZAZZI, MAURIZIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 25.295
EU - Europa 19.043
AS - Asia 11.024
SA - Sud America 2.104
AF - Africa 801
OC - Oceania 34
Continente sconosciuto - Info sul continente non disponibili 12
Totale 58.313
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 24.928
GB - Regno Unito 4.325
RU - Federazione Russa 3.931
CN - Cina 3.411
SG - Singapore 3.285
IE - Irlanda 2.543
IT - Italia 2.010
BR - Brasile 1.730
VN - Vietnam 1.315
SE - Svezia 1.298
DE - Germania 1.238
UA - Ucraina 1.193
FR - Francia 1.138
HK - Hong Kong 1.041
FI - Finlandia 583
KR - Corea 519
ZA - Sudafrica 459
IN - India 391
BD - Bangladesh 182
ES - Italia 176
CA - Canada 172
AR - Argentina 136
NG - Nigeria 124
IQ - Iraq 120
MX - Messico 111
NL - Olanda 111
TR - Turchia 105
JP - Giappone 94
BE - Belgio 91
AT - Austria 82
PK - Pakistan 79
PL - Polonia 74
ID - Indonesia 72
EC - Ecuador 59
UZ - Uzbekistan 52
KE - Kenya 45
SA - Arabia Saudita 40
VE - Venezuela 40
CL - Cile 37
CO - Colombia 36
CZ - Repubblica Ceca 36
AE - Emirati Arabi Uniti 33
MA - Marocco 31
LT - Lituania 30
MY - Malesia 30
PH - Filippine 29
AU - Australia 27
JO - Giordania 25
PY - Paraguay 25
EG - Egitto 22
IR - Iran 22
CI - Costa d'Avorio 18
KZ - Kazakistan 18
NP - Nepal 18
EE - Estonia 17
ET - Etiopia 17
TH - Thailandia 17
GR - Grecia 16
LU - Lussemburgo 16
DZ - Algeria 15
LB - Libano 15
PA - Panama 15
DO - Repubblica Dominicana 14
IL - Israele 14
JM - Giamaica 14
UY - Uruguay 14
PT - Portogallo 13
SK - Slovacchia (Repubblica Slovacca) 13
AL - Albania 12
BO - Bolivia 12
KG - Kirghizistan 12
PE - Perù 12
TN - Tunisia 12
AZ - Azerbaigian 11
CH - Svizzera 11
DK - Danimarca 11
LV - Lettonia 11
RO - Romania 11
RS - Serbia 11
UG - Uganda 11
EU - Europa 9
BG - Bulgaria 8
BH - Bahrain 8
CR - Costa Rica 8
HN - Honduras 8
SN - Senegal 8
BY - Bielorussia 7
GE - Georgia 7
HU - Ungheria 7
LK - Sri Lanka 7
OM - Oman 7
PS - Palestinian Territory 7
TW - Taiwan 7
GT - Guatemala 6
SY - Repubblica araba siriana 6
AO - Angola 5
GA - Gabon 5
TT - Trinidad e Tobago 5
AM - Armenia 4
BW - Botswana 4
Totale 58.220
Salva come PNG Salva come JPEG
Città #
Southend 3.724
Dallas 3.030
Fairfield 2.521
Dublin 2.510
Singapore 1.809
Ashburn 1.747
Houston 1.664
Chandler 1.518
Woodbridge 1.130
Santa Clara 1.073
Moscow 1.045
Hong Kong 1.002
Jacksonville 964
Seattle 939
Wilmington 930
Cambridge 851
Ann Arbor 843
Beijing 831
San Jose 748
Siena 610
Hefei 602
Seoul 511
Munich 467
Princeton 433
The Dalles 417
Johannesburg 406
Ho Chi Minh City 387
Los Angeles 372
New York 323
Lauterbourg 304
Nanjing 294
Helsinki 285
Council Bluffs 281
Hanoi 275
Menlo Park 222
Dong Ket 187
Boardman 183
San Mateo 181
Milan 165
São Paulo 160
Buffalo 146
San Diego 139
Rome 123
Abuja 119
Shanghai 119
Bengaluru 114
Columbus 114
Nanchang 113
London 109
Málaga 109
Redondo Beach 104
Dearborn 93
Frankfurt am Main 87
Orem 86
Tokyo 80
Brussels 79
Nuremberg 74
Düsseldorf 72
Chennai 70
Tianjin 67
Florence 63
Chicago 62
Turku 61
Da Nang 60
Shenyang 60
Warsaw 57
Montreal 56
Toronto 53
Hebei 51
San Francisco 51
Vienna 51
Changsha 50
Rio de Janeiro 50
Hangzhou 49
Atlanta 48
Denver 47
Lappeenranta 47
Phoenix 46
Amsterdam 45
Haiphong 45
Brooklyn 43
Manchester 43
Tashkent 43
Baghdad 42
Belo Horizonte 42
Jiaxing 42
Lancaster 41
Portsmouth 40
Dhaka 39
Mexico City 38
Zhengzhou 38
Jinan 37
Norwalk 37
Guangzhou 36
Kunming 36
Bologna 35
Stockholm 34
Brasília 33
Falls Church 30
Mumbai 29
Totale 39.771
Salva come PNG Salva come JPEG
Nome #
A Prognostic Model for Estimating the Time to Virologic Failure in HIV-1 Infected Patients Undergoing a New Combination Antiretroviral Therapy Regimen 621
Plasma levels of soluble CD27: a simple marker to monitor immune activation during potent antiretroviral therapy in HIV-infected subjects 619
"EFFICACY AND SAFETY OF 2-DRUG COMBINATION ANTIRETROVIRAL THERAPY IN CLINICAL PRACTICE: RESULTS FROM A SINGLE CENTER STUDY" 561
Surrogate markers as a guide to evaluate response to antiretroviral therapy 481
Agreement between an in-house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to HIV-1 protease, reverse transcriptase, and integrase inhibitors 325
Human DDX3 protein is a valuable target to develop broad spectrum antiviral agents 317
Antigenicity and immunogenicity of the V3 domain of HIV-1 gp120 expressed on the surface of Streptococcus gordonii. AIDS Res Hum Retroviruses 311
Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe 308
A child with vestibular neuritis. Is adenovirus implicated? 305
Structure-Based Identification of HIV-1 Nucleocapsid Protein Inhibitors Active against Wild-Type and Drug-Resistant HIV-1 Strains 298
A novel methodology for large-scale phylogeny partition 297
Comparable in vitro activity of second-generation HIV-1 integrase strand transfer inhibitors (INSTIs) on HIV-1 clinical isolates with INSTI resistance mutations 295
The HIV-1 reverse transcriptase E138A natural polymorphism decreases the genetic barrier to resistance to etravirine in vitro 294
Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor 293
DDX3X inhibitors, an effective way to overcome HIV-1 resistance 292
Impact of transmitted drug resistance in naïve-patients starting 2 NRTI plus a boosted protease-inhibitor (PI) or integrase-inhibitor (INSTI). 290
Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and ex vivo CD4 T cells 290
Predicting 2-drug antiretroviral regimen efficacy by genotypic susceptibility score: results from a cohort study 288
(Thia)calixarenephosphonic Acids as Potent Inhibitors of the Nucleic Acid Chaperone Activity of the HIV-1 Nucleocapsid Protein with a New Binding Mode and Multitarget Antiviral Activity 284
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 281
A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy 278
Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: A cohort study 278
Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort 278
Changing patterns in HIV-1 non-B clade prevalence and diversity in Italy over three decades 271
Analysis of genetic and viral determinants of HBsAg levels in patients with chronic HBV infection 271
Genotypic resistance to zidovudine as a predictor of failure of subsequent therapy with human immunodeficiency virus type 1 nucleoside reverse transcriptase inhibitors 270
Virological and Immunological Response to Antiretroviral Regimens Containing Maraviroc in HIV Type 1-Infected Patients in Clinical Practice: Role of Different Tropism Testing Results and of Concomitant Treatments 267
Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples 264
Anticipating policy considerations for a future HIV vaccine: a preliminary study 260
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 259
Decline of Prevalence of Resistance Associated Substitutions to NS3 and NS5A inhibitors at DAA-failure in Hepatitis C Virus in Italy over the years 2015 to 2018 259
5,6-Dihydroxypyrimidine Scaffold to Target HIV-1 Nucleocapsid Protein 259
Synthesis and Antiviral Activity of Novel 1,3,4-Thiadiazole Inhibitors of DDX3X 256
Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score 255
Stability of unfrozen whole blood DNA for remote genotypic analysis of HIV-1 coreceptor tropism 255
Comparative analysis of different cell systems for Zika virus (ZIKV) propagation and evaluation of anti-ZIKV compounds in vitro 253
Development of an internally controlled quantitative PCR to measure total cell-associated HIV-1 DNA in blood 252
Comparative determination of HIV-1 coreceptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping 252
Detection of genotypically drug-resistant HIV-1 variants and non-B subtypes in recently infected antiretroviral-naive adults in Italy. 252
Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA 250
Development and significance of the HIV-1 reverse transcriptase M184V mutation during combination therapy with lamivudine, zidovudine and protease inhibitors 249
Cellular and Molecular Mechanisms of In Vivo and In Vitro SARS-CoV-2 Infection: A Lesson from Human Sperm 248
Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy 248
Performance of Geno2Pheno[coreceptor] to infer coreceptor use in human immunodeficiency virus type 1 (HIV-1) subtype A 248
Analysis of the HIV-1 nef gene in five intravenous drug users with long-term nonprogressive HIV-1 infection in Italy. 247
Three-class-resistant human immunodeficiency virus type 1 variant in a drug-naive heterosexual couple 243
An update to the HIV-TRePS system: The development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype 243
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 241
Detection of residual human immunodeficiency virus type 1 reverse transcriptase K103N minority species in plasma RNA and peripheral blood mononuclear cell DNA following discontinuation of non-nucleoside therapy 241
Low-cost simultaneous detection of CCR5-delta32 and HLA-B*5701 alleles in human immunodeficiency virus type 1 infected patients by selective multiplex endpoint PCR 240
Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients 239
HIV-1 and human myelin proteins share an antigenic determinant 238
Antiretroviral therapy optimisation without genotype resistance testing: a perspective on treatment history based models. 238
Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro 238
Impact of resistance mutations on virological efficacy of DTG-based maintenance two-drug regimens: a cohort study 237
Near Full-Length Sequence Analysis of HIV Type 1 BF Recombinants from Italy 236
In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations 236
The HIV-1 integrase E157Q polymorphism per se does not alter susceptibility to raltegravir and dolutegravir in vitro 233
Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors 233
Predicting 2-drug antiretroviral regimen efficacy by genotypic susceptibility score: results from a cohort study 233
Concordance between polymerase chain reaction and antibody detection in the diagnosis of human immunodeficiency virus type 1 infection. 231
Antiretroviral therapy with protease inhibitors in human immunodeficiency virus type 1- and human herpesvirus 8 coinfected patients 231
Discordances with HIV-1 RNA quantitative determinations by three commercial assays in Pointe Noire, Republic of Congo 230
Natural variability in the HR-1 and HR-2 domains of HIV type 1 gp41 from different clades circulating in Italy 229
Identification of a Possible Ancestor of the Subtype A1 HIV Type 1 Variant Circulating in the Former Soviet Union 228
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016 228
Synthesis and Evaluation of Bifunctional Aminothiazoles as Antiretrovirals Targeting the HIV-1 Nucleocapsid Protein 228
Lack of evidence of HHV-8 DNA in blood cells from heart transplant recipients 227
Focal myositis: a polymerase chain reaction analysis for a viral etiology 226
Decline of Prevalence of Resistance Associated Substitutions to NS3 and NS5A inhibitors at DAA-failure in Hepatitis C Virus in Italy over the years 2015 to 2018 226
Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice 225
Advantages of Predicted Phenotypes and Statistical Learning Models in Inferring Virological Response to Antiretroviral Therapy from HIV Genotype 223
Development and significance of resistance to protease inhibitors in HIV-1-infected adults under triple-drug therapy in clinical practice. 223
Evaluation of the presence of 2-LTR HIV-1 unintegrated DNA as a simple molecular predictor of disease progression. 221
Prevalence of skin allograft discards as a result of serological and molecular microbiological screening in a regional skin bank in Italy 220
Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors 219
Evidence of differential selection of HIV-1 variants carrying drug resistant mutations in seroconverters 217
Rilpivirine resistance and the dangerous liaisons with substitutions at position 184 among patients infected with HIV-1: analysis from a national drug-resistance database (ARCA) 217
Exploring the implication of DDX3X in DENV infection: discovery of the first-in-class DDX3X fluorescent inhibitor 217
An update to the HIV-TRePS system: The development of new computational models that do not require a genotype to predict HIV treatment outcomes 216
Long-read direct infrared sequencing of crude PCR products for prediction of resistance to HIV-1 reverse transcriptase and protease inhibitors. 216
Bithiazole Inhibitors of Phosphatidylinositol 4-Kinase (PI4KIIIβ) as Broad-Spectrum Antivirals Blocking the Replication of SARS-CoV-2, Zika Virus and Human Rhinoviruses 212
FALLIMENTO VIROLOGICO PRECOCE CON SELEZIONE RAPIDA DI FARMACORESISTENZA IN UN PAZIENTE CON HCV GENOTIPO 1, TRATTATO CON PEGINTERFERON, RIBAVIRINA E TELAPREVIR 211
Impact of resistance mutations on virological efficacy of DTG-based maintenance two-drug regimens: an ARCA cohort study 211
Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy 210
The global spread of HIV-1 subtype B epidemic 209
Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database 208
Distribution of different HBV DNA forms in plasma and peripheral blood mononuclear cells (PBMCs) of chronically infected patients with low or undetectable HBV plasma viremia 208
Immunoglobulin gene rearrangement analysis in composite Hodgkin disease and large B-cell lymphoma: evidence for receptor revision of immunoglobulin heavy chain variable region genes in Hodgkin-Reed-Sternberg cells? 208
Neuronal intranuclear inclusion disease: polymerase chain reaction and ultrastructural study of rectal biopsy specimen in a new case 207
Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients – evidence from a large observational cohort 207
Prevalence of HIV-1 Subtypes and Drug Resistance-Associated Mutations in HIV-1-Positive Treatment-Naive Pregnant Women in Pointe Noire, Republic of the Congo (Kento-Mwana Project) 205
A Comparison of Sanger Sequencing and Amplicon-Based Next Generation Sequencing Approaches for the Detection of HIV-1 Drug Resistance Mutations 204
Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA 204
European guidelines on the clinical management of HIV-1 tropism testing 203
Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG- or ATV-based dual therapy 200
Hepatitis B virus vaccination in HIV-1-infected young adults: A tool to reduce the size of HIV-1 reservoirs? 199
Development of a Cell-Based Immunodetection Assay for Simultaneous Screening of Antiviral Compounds Inhibiting Zika and Dengue Virus Replication. 199
Divergent distribution of HIV-1 drug-resistant variants on and off antiretroviral therapy 198
Evaluation of a commercial real-time PCR kit for the detection of the Q80K polymorphism in plasma from HCV genotype 1a infected patients 198
Totale 25.697
Salva come PNG Salva come JPEG
Categoria #
all - tutte 183.492
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 183.492
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021762 0 0 0 0 0 0 0 0 0 0 302 460
2021/20223.890 212 469 268 397 198 147 209 173 301 396 360 760
2022/20235.234 312 514 617 725 505 1.030 148 432 491 158 201 101
2023/20243.724 157 98 315 210 78 1.083 1.277 103 18 63 82 240
2024/20258.759 189 400 838 425 1.002 552 376 562 811 436 910 2.258
2025/202619.233 1.649 2.757 2.628 2.291 3.804 761 2.242 829 714 1.075 483 0
Totale 59.100